All In Biotech

Drug Trial Radar · NCT05067868

A Study of Replagal in Children and Adults With Fabry Disease in India

A Prospective, Open-label, Multicentre, Interventional, Single-arm, Phase IV Study to Evaluate the Safety and Efficacy of Replagal (Agalsidase Alfa [r-DNA Origin]) in Indian Children and Adults With Fabry Disease

Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

5

Planned (sponsor's estimate)

Start

Nov 1, 2022

Primary completion

Oct 31, 2027

Study completion Oct 31, 2027

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
Collaborators
Takeda
First posted
Oct 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of this study is to learn more about the safety profile of Replagal. Participants will receive Replagal every 2 weeks at the clinic for about 1 year.

Conditions

  • Fabry Disease

Interventions

  • ReplagalBiological

    Participants will receive Replagal 0.2 mg/kg, intravenous infusion at Day 1 and every 2 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From the start of study up to 53 weeks
  2. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)Time frame: From the study drug administration up to Week 53
  3. Number of Participants With Adverse Drug Reactions (ADRs) Related to ReplagalTime frame: From the study drug administration up to Week 53
  4. Number of Participants With Infusion-related Reactions of ReplagalTime frame: From the study drug administration up to Week 53

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Institute of Child Health

    Kolkata, India · Not yet recruiting

  • All India Institute of Medical Sciences (AIIMS)

    New Delhi, India · Recruiting

  • Sir Gangaram Hospital

    New Delhi, India · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.